L3VLUP
ProSign in

LGND · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

LGNDJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • LGND
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterLGNDJNJ
Q3 20204 holders, $189m30 holders, $26.2bn
Q4 20202 holders, $169m32 holders, $26.6bn
Q1 20212 holders, $204m31 holders, $25.3bn
Q2 20211 holders, $189m37 holders, $25.6bn
Q3 20211 holders, $204m40 holders, $24.1bn
Q4 20211 holders, $223m33 holders, $25.2bn
Q1 20221 holders, $156m35 holders, $28.2bn
Q2 20221 holders, $124m33 holders, $26.9bn
Q3 20221 holders, $109m36 holders, $25.4bn
Q4 20221 holders, $84m35 holders, $27.6bn
Q1 20231 holders, $93m42 holders, $24.5bn
Q2 20231 holders, $97m38 holders, $25.0bn
Q3 20231 holders, $80m37 holders, $18.9bn
Q4 20232 holders, $97m31 holders, $19.0bn
Q1 20241 holders, $74m32 holders, $19.7bn
Q2 20241 holders, $85m35 holders, $20.4bn
Q3 20241 holders, $101m28 holders, $22.3bn
Q4 20241 holders, $109m37 holders, $20.4bn
Q1 20251 holders, $111m32 holders, $20.5bn
Q2 20251 holders, $121m31 holders, $18.4bn
Q3 20253 holders, $283m32 holders, $23.7bn
Q4 20253 holders, $287m29 holders, $27.8bn
Q1 20263 holders, $288m34 holders, $35.6bn
Q2 20265 holders, $908m33 holders, $39.1bn
LGND

Ligand Pharmaceuticals Inc

Holders
1
Reported value
$109m
Buyers
1
Sellers
0

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
37
Reported value
$20.4bn
Buyers
23
Sellers
12

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only LGND (0)

None.

Only JNJ (36)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, and 11 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →